October 25, 2012
As the body ages, changes in the production of hormones occur. The period when a woman's body begins the transition to menopause is called perimenopause. Women usually enter perimenopause in their 40s and the following changes can occur:
Most research suggests that HIV-negative women who undergo perimenopause do so without experiencing mood disorders. However, some studies have found that women transitioning toward menopause have an increased risk for depression. This increased risk can occur even among women who have no history of mood disorders such as depression.
A team of researchers in the U.S. enrolled HIV-positive women and women at high risk of HIV infection and found that, regardless of HIV status, women undergoing perimenopause were at increased risk for experiencing symptoms of depression. In turn, the depression experienced by HIV-positive women affected their ability to take potent combination therapy for HIV (commonly called ART or HAART) exactly as directed. The research team encourages doctors and nurses to screen their female HIV-positive patients who are experiencing changes in their monthly cycles for depression and to offer them treatment if it is present.
The research team, part of the Women's Interagency HIV study (WIHS), enrolled women in 1994 to 1995 and again between 2001 and 2002 in the following American cities:
The researchers recruited HIV-positive and HIV-negative women of similar age, ethnicity, level of education and HIV risk factors (including injection of street drugs).
Between April 2007 and April 2008 the WIHS team incorporated surveys about menopause and mood. As part of the overall WIHS, every six months women were interviewed, underwent physical examinations and gave blood and other fluids for analysis.
For their study on menopause, researchers focused their analyses on 835 HIV-positive women and compared them to 335 HIV-negative women.
The WIHS team used the following terms and definitions:
The average profile of HIV-positive women when they entered the menopause sub-study was as follows:
Rates of depression were the same (38%) among HIV-positive and HIV-negative women.
The distribution of depression by stage of menopause (regardless of HIV status) was as follows:
Taking many biological and social factors into consideration, the researchers found that women undergoing early perimenopause, regardless of HIV status, had the most severe symptoms of depression. This was also the case when researchers restricted their analysis to HIV-positive women.
Here are some other findings:
The researchers are not certain why symptoms of depression were more severe in perimenopause. However, the WIHS team is conducting long-term research, monitoring the impact of changing cycles on the health of HIV-positive women.
A Danish clinical trial monitoring women who received hormone therapy was recently completed. In that study, Danish researchers recruited 1,006 HIV-negative women around the age of 50 and randomly assigned half to receive hormone therapy. The randomized phase of the trial lasted for 10 years. After this, the women were monitored for six more years, for a total of 16 years of observation. The research team found a reduced risk of death without an increased risk for heart attack or cancer among the women who received hormone therapy compared to those who did not. This beneficial effect occurred during the first 10 years of the study and was maintained. This finding was somewhat surprising because past randomized controlled trials of hormone therapy have not found such therapy to be beneficial; in fact, hormone therapy was associated with an increased risk of harm (heart attacks, stroke, cancer).
Also, researchers have recently completed re-analyses of previous clinical trials of hormone therapy for women who were undergoing menopause. Those re-analyses suggest that hormone therapy may be safer than previously thought when restricted only to women who are just entering menopause, who are relatively young (around the age of 50) and who are otherwise in good health.
Both the Danish study and the re-analyses have prompted renewed interest and debate about the safety of hormone therapy for women. Some researchers are now suggesting that hormone therapy might be appropriate when started in the early stages of menopause. However, it will take months, perhaps years, for this debate to be settled, as doctors and patients weigh the risk and benefits of hormone therapy.
Note that nearly all studies about intervening with estrogen (and other hormones and therapies) to treat mood disorders that can occur during the menopause transition have enrolled generally healthy HIV-negative women.
The WIHS team warned that estrogen-based therapies are known to cause an increased risk for unnecessary blood clots, which can lead to a heart attack or stroke. Infection with HIV in people and infection with the closely related virus SIV in susceptible monkeys is also associated with an increased risk for cardiovascular disease. Therefore, caution is needed when conducting clinical trials of or prescribing estrogen-based therapy in HIV-positive women who are in the transition to menopause.